BRCA1 is a major gatekeeper of genomic stability. Acting in multiple central processes like double-strand break repair, centrosome replication, and checkpoint control, BRCA1 participates in maintaining genomic integrity and protects the cell against genomic instability. Chromosomal instability (CIN) as part of genomic instability is an inherent characteristic of most solid tumors and is also involved in breast cancer development. In this study, we determined the extent of CIN in 32 breast cancer tumors of women with a BRCA1 germline mutation compared to 62 unselected breast cancers. We applied fluorescence in situ hybridization (FISH) with centromere-specific probes for the chromosomes 1, 7, 8, 10, 17, and X and locus-specific probes for 3q27 (BCL6), 5p15.2 (D5S23), 5q31 (EGR1), 10q23.3 (PTEN), and 14q32 (IGH @) on formalin-fixed paraffin-embedded tissue microarray sections. Our hypothesis of an increased level of CIN in BRCA1-associated breast cancer could not be confirmed by this approach. Surprisingly, we detected no significant difference in the extent of CIN in BRCA1-mutated versus sporadic tumors. The only exception was the CIN value for chromosome 1. Here, the extent of CIN was slightly higher in the group of sporadic tumors.

Keywords:
Hereditary breast cancer, BRCA1, Chromosomal instability, CIN, Fluorescence in situ hybridization
1.
Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, et al: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376:245–251 (2010).
2.
Brozek I, Ochman K, Debniak J, Morzuch L, Ratajska M, et al: Loss of heterozygosity at BRCA1/2 loci in hereditary and sporadic ovarian cancers. J Appl Genet 50:379–384 (2009).
3.
Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, et al: Pathologic complete response rates in young women with BRCA1-positive breast cancer after neoadjuvant chemotherapy. J Clin Oncol 28:375–379 (2010).
4.
Chiba S, Okuda M, Mussman JG, Fukasawa K: Genomic convergence and suppression of centrosome hyperamplification in primary p53-/- cells in prolonged culture. Exp Cell Res 258:310–321 (2000).
5.
Cortez D, Wang Y, Qin J, Elledge SJ: Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 286:1162–1166 (1999).
6.
Deng CX: Roles of BRCA1 in centrosome duplication. Oncogene 21:6222–6227 (2002).
7.
Derheimer FA, Kastan MB: Multiple roles of ATM in monitoring and maintaining DNA integrity. FEBS Lett 584:3675–3681 (2010).
8.
Farabegoli F, Santini D, Ceccarelli C, Taffurelli M, Marrano D, Baldini N: Clone heterogeneity in diploid and aneuploid breast carcinomas as detected by FISH. Cytometry 46:50–56 (2001).
9.
Fehm T, Morrison L, Saboorian H, Hynan L, Tucker T, Uhr J: Patterns of aneusomy for three chromosomes in individual cells from breast cancer tumors: Breast Cancer Res Treat 75:227–239 (2002).
10.
Gadzicki D, Schubert A, Fischer C, Milde S, Lehmann U, et al: Histopathological criteria and selection algorithms for BRCA1 genetic testing. Cancer Genet Cytogenet 189:105–111 (2009).
11.
Ganem NJ, Godinho SA, Pellman D: A mechanism linking extra centrosomes to chromosomal instability. Nature 460:278–282 (2009).
12.
Geigl JB, Obenauf AC, Schwarzbraun T, Speicher MR: Defining ‘chromosomal instability’. Trends Genet 24:64–69 (2008).
13.
Gudmundsdottir K, Ashworth A: The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 25:5864–5874 (2006).
14.
Guo HQ, Gao M, Ma J, Xiao T, Zhao LL, et al: Analysis of the cellular centrosome in fine-needle aspirations of the breast. Breast Cancer Res 9:R48 (2007).
15.
Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 144:646–674 (2011).
16.
Heim S, Mandahl N, Mitelman F: Genetic convergence and divergence in tumor progression. Cancer Res 48:5911–5916 (1988).
17.
Johannsdottir HK, Jonsson G, Johannesdottir G, Agnarsson BA, Eerola H, et al: Chromosome 5 imbalance mapping in breast tumors from BRCA1 and BRCA2 mutation carriers and sporadic breast tumors. Int J Cancer 119:1052–1060 (2006).
18.
Jönsson G, Staaf J, Olsson E, Heidenblad M, Vallon-Christersson J, et al: High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization. Genes Chromosomes Cancer 46:543–558 (2007).
19.
Joosse SA, van Beers EH, Tielen IH, Horlings H, Peterse JL, et al: Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH. Breast Cancer Res Treat 116:479–489 (2009).
20.
Kais Z, Parvin JD: Regulation of centrosomes by the BRCA1-dependent ubiquitin ligase. Cancer Biol Ther 7:1540–1543 (2008).
21.
Ko MJ, Murata K, Hwang D, Parvin JD: Inhibition of BRCA1 in breast cell lines causes the centrosome duplication cycle to be disconnected from the cell cycle. Oncogene 25:298–303 (2006).
22.
Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, et al: The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20:2310–2318 (2002).
23.
Lee JS, Collins KM, Brown AL, Lee CH, Chung JH: hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature 404:201–204 (2000).
24.
Lengauer C, Kinzler KW, Vogelstein B: Genetic instability in colorectal cancers. Nature 386:623–627 (1997).
25.
Lengauer C, Kinzler KW, Vogelstein B: Genetic instabilities in human cancers. Nature 396:643–649 (1998).
26.
Lingle WL, Barrett SL, Negron VC, D’Assoro AB, Boeneman K, et al: Centrosome amplification drives chromosomal instability in breast tumor development. Proc Natl Acad Sci USA 99:1978–1983 (2002).
27.
McIntosh A, Shaw C, Evans G, Turnbull N, Bahar N, et al: Clinical guidelines for the classification and care of women at risk of familial breast cancer. London: National Collaborating Centre for Primary Care, University of Sheffield (2004).
28.
Melchor L, Álvarez S, Honrado E, Palacios J, Barroso A, et al: The accumulation of specific amplifications characterizes two different genomic pathways of evolution of familial breast tumors. Clin Cancer Res 11:8577–8584 (2005).
29.
Melchor L, Honrado E, García MJ, Alvarez S, Palacios J, et al: Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes. Oncogene 27:3165–3175 (2008).
30.
Mitelman F, Johansson B, Mertens F (eds): Mitelman Database of Chromosome Aberrations and Gene fusions in Cancer (2011). Available at http://cgap.nci.nih.gov/Chromosomes/Mitelman.
31.
Miyoshi Y, Iwao K, Ikeda N, Egawa C, Noguchi S: Acceleration of chromosomal instability of BRCA1-associated hereditary breast cancer by p53 abnormality. Breast J 8:77–89 (2002).
32.
Moynahan ME, Cui TY, Jasin M: Homology-directed DNA repair, mitomycin-C resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res 61:4842–4850 (2001).
33.
Nakamura H, Saji H, Idiris A, Kawasaki N, Hosaka M, et al: Chromosomal instability detected by fluorescence in situ hybridization in surgical specimens of non-small cell lung cancer is associated with poor survival. Clin Cancer Res 9:2294–2299 (2003).
34.
Oikawa T, Okuda M, Ma Z, Goorha R, Tsujimoto H, et al: Transcriptional control of BubR1 by p53 and suppression of centrosome amplification by BubR1. Mol Cell Biol 25:4046–4061 (2005).
35.
Pihan GA, Wallace J, Zhou Y, Doxsey SJ: Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas. Cancer Res 63:1398–1404 (2003).
36.
Rennstam K, Ahlstedt-Soini M, Baldetorp B, Bendahl PO, Borg A, et al: Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization. Cancer Res 63:8861–8868 (2003).
37.
Sankaran S, Crone DE, Palazzo RE, Parvin JD: BRCA1 regulates gamma-tubulin binding to centrosomes. Cancer Biol Ther 6:1853–1857 (2007).
38.
Scully R, Livingston DM: In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 408:429–432 (2000).
39.
Shimomura A, Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S: Association of loss of BRCA1 expression with centrosome aberration in human breast cancer. J Cancer Res Clin Oncol 135:421–430 (2008).
40.
Steinemann D, Skawran B, Becker T, Tauscher M, Weigmann A, et al: Assessment of differentiation and progression of hepatic tumors using array-based comparative genomic hybridization. Clin Gastroenterol Hepatol 4:1283–1291 (2006).
41.
Stolz A, Ertych N, Kienitz A, Vogel C, Schneider V, et al: The CHK2-BRCA1 tumour suppressor pathway ensures chromosomal stability in human somatic cells. Nat Cell Biol 12:492–499 (2010).
42.
Takehisa M, Sasa M, Bando Y, Hirose T, Morimoto T, et al: Chromosomal aneusomy (Chr 1, 11, 17) detected by fluorescence in situ hybridization may be a prognostic factor in breast cancer. Anticancer Res 27:1073–1078 (2007).
43.
Thompson SL, Bakhoum SF, Compton DA: Mechanisms of chromosomal instability. Curr Biol 20:R285–R295 (2010).
44.
Tirkkonen M, Johannsson O, Agnarsson BA, Olsson H, Ingvarsson S, et al: Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 57:1222–1227 (1997).
45.
Tsuji K, Kawauchi S, Saito S, Furuya T, Ikemoto K, et al: Breast cancer cell lines carry cell line-specific genomic alterations that are distinct from aberrations in breast cancer tissues: comparison of the CGH profiles between cancer cell lines and primary cancer tissues. BMC Cancer 10:15 (2010).
46.
Turnbull C, Rahman N: Genetic predisposition to breast cancer: past, present, and future. Annu Rev Genomics Hum Genet 9:321–345 (2008).
47.
Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, et al: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376:235–244 (2010).
48.
van Beers EH, van Welsem T, Wessels LF, Li Y, Oldenburg RA, et al: Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations. Cancer Res 65:822–827 (2005).
49.
Venkitaraman AR: A growing network of cancer-susceptibility genes. N Engl J Med 348:1917–1919 (2003).
50.
Waddell N, Arnold J, Cocciardi S, da Silva L, Marsh A, et al: Subtypes of familial breast tumours revealed by expression and copy number profiling. Breast Cancer Res Treat 123:661–677 (2009).
51.
Ward BE, Gersen SL, Carelli MP, McGuire NM, Dackowski WR, et al: Rapid prenatal diagnosis of chromosomal aneuploidies by fluorescence in situ hybridization: clinical experience with 4,500 specimens. Am J Hum Genet 52:854–865 (1993).
52.
Wessels LF, van Welsem T, Hart AA, van’t Veer LJ, Reinders MJ, Nederlof PM: Molecular classification of breast carcinomas by comparative genomic hybridization. Cancer Res 62:7110–7117 (2002).
53.
Wilkens L, Flemming P, Gebel M, Bleck J, Terkamp C, et al: Induction of aneuploidy by increasing chromosomal instability during dedifferentiation of hepatocellular carcinoma. Proc Natl Acad Sci USA 101:1309–1314 (2004).
54.
Wilkens L, Gerr H, Gadzicki D, Kreipe H, Schlegelberger B: Standardised fluorescence in situ hybridisation in cytological and histological specimens. Virchows Arch 447:586–592 (2005).
55.
Xu X, Weaver Z, Linke SP, Li C, Gotay J, et al: Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell 3:389–395 (1999).
56.
Young SR, Pilarski RT, Donenberg T, Shapiro C, Hammond LS, et al: The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer 9:86 (2009).
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.